

Resource Summary Report

Generated by [nidm-terms](#) on Aug 26, 2026

Brilliant Violet 711(TM) anti-mouse CD366 (Tim-3)

RRID:AB_2890691

Type: Antibody

Proper Citation

BioLegend Cat# 134021, RRID:AB_2890691

Antibody Information

URL: http://antibodyregistry.org/AB_2890691

Proper Citation: BioLegend Cat# 134021, RRID:AB_2890691

Target Antigen: CD366

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 711(TM) anti-mouse CD366 (Tim-3)

Description: This monoclonal targets CD366

Target Organism: mouse

Clone ID: Clone B8.2C12

Antibody ID: AB_2890691

Vendor: BioLegend

Catalog Number: 134021

Record Creation Time: 20250819T232855+0000

Record Last Update: 20250820T052827+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 711(TM) anti-mouse CD366 (Tim-3).

No alerts have been found for Brilliant Violet 711(TM) anti-mouse CD366 (Tim-3).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Kirschstein E, et al. (2026) Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer. Cancer cell, 44(5), 1080.

Saini M, et al. (2025) StealTHY: An immunogen-free CRISPR platform to expose concealed metastasis regulators in immunocompetent models. Cell, 188(26), 7591.

Zheng C, et al. (2024) IFN γ -induced BST2+ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling. Cell reports, 43(4), 114088.

Sanchez-Moral L, et al. (2023) Macrophage CD5L is a target for cancer immunotherapy. EBioMedicine, 91, 104555.